SCHEMBL4887061

SCHEMBL4887061

OC(CN1CCCNCC1)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 5/20 0.48
CHRM1 P11229 5/20 0.48
CHRM4 P08173 3/20 0.48
CHRM5 P08912 3/20 0.48
CHRM3 P20309 3/20 0.48
RAD52 P43351 1/20 0.43
KCNH2 Q12809 3/20 0.42
LMNA P02545 3/20 0.42
HTR1A P08908 2/20 0.42
CYP2D6 P10635 2/20 0.42
OPRM1 P35372 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
CXCR4 P61073 6/20 0.41
ADRA2C P18825 1/20 0.41
CCR2 P41597 1/20 0.41
CXCL12 P48061 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883044 0.94 CHRM2 (0.52) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4889508 0.84 KMT2A (0.46) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4881961 0.82 MEN1 (0.49) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4889815 0.77 MEN1 (0.52) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4883173 0.77 GAA (0.58) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL6765682 0.75 CHRM2 (0.74) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4881869 0.73 CHRM2 (0.49) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL14003869 0.70 CHRM2 (0.46) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL4882752 0.70 CHRM3 (0.43) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL10519217 0.69 CHRM2 (0.64) CHRM2CHRM1CHRM4CHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US claimed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP claimed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP disclosed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 CHRM2 3/4885CHRM1 5/4885CHRM4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.